Dr. Ke Li is an accomplished researcher specializing in orthopaedic surgery with a Ph.D. from Yangzhou University, holding prior degrees in Orthopaedic Surgery (M.M., China Medical University) and Clinical Medicine (B.M., Fujian University of Traditional Chinese Medicine). His research primarily focuses on constructing bio-nanomaterials that target various effector cells in the bone aging microenvironment to develop innovative anti-osteoporosis therapies. As the Principal Investigator of the Jiangsu Provincial Postgraduate Research & Practice Innovation Program, he leads a project on developing a nanozyme-based gene-editing platform for bone cell coupling and osteoporosis treatment. Dr. Li has an impressive portfolio of 23 scholarly publications, accumulating 391 citations and an h-index of 11, underscoring his scientific impact and research excellence. His notable works include pioneering studies on nitric oxide nanopumps for bone marrow regeneration (Nature Communications), cellular senescence mechanisms in skeletal diseases (Bone Research), and nanozyme-based gene editing for reversing osteoporosis (Nano Today). Additionally, his research extends to drug delivery systems, chemo-immunotherapy, and tumor microenvironment modulation, with publications in high-impact journals such as Bioactive Materials, Materials & Design, and Frontiers in Oncology. Dr. Li’s contributions significantly advance the understanding of bone aging, nanomedicine, and regenerative therapy, providing a foundation for translational applications in orthopaedics and related biomedical fields. His innovative approach to integrating nanotechnology with molecular biology continues to drive breakthroughs in therapeutic strategies for skeletal and degenerative diseases.